Citigroup’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$305M Buy
682,807
+142,877
+26% +$66.6M 0.13% 153
2025
Q4
$245M Sell
539,930
-65
-0% -$28K 0.11% 166
2025
Q3
$211M Sell
539,995
-59,084
-10% -$24.7M 0.09% 208
2025
Q2
$267M Sell
599,079
-28,636
-5% -$13.2M 0.13% 150
2025
Q1
$304M Buy
627,715
+165,647
+36% +$77.2M 0.16% 113
2024
Q4
$186M Sell
462,068
-126,352
-21% -$58.6M 0.11% 169
2024
Q3
$274M Buy
588,420
+108,813
+23% +$52.3M 0.16% 117
2024
Q2
$225M Buy
479,607
+79,839
+20% +$34.7M 0.14% 134
2024
Q1
$167M Sell
399,768
-54,824
-12% -$23.2M 0.11% 174
2023
Q4
$185M Buy
454,592
+8,995
+2% +$3.32M 0.13% 138
2023
Q3
$155M Sell
445,597
-17,399
-4% -$6.09M 0.12% 146
2023
Q2
$163M Buy
462,996
+38,119
+9% +$12.8M 0.11% 142
2023
Q1
$134M Sell
424,877
-59,620
-12% -$17.9M 0.09% 170
2022
Q4
$140M Buy
484,497
+1,256
+0.3% +$383K 0.11% 167
2022
Q3
$140M Buy
483,241
+365
+0.1% +$105K 0.1% 157
2022
Q2
$136M Sell
482,876
-35,160
-7% -$9.41M 0.1% 170
2022
Q1
$135M Sell
518,036
-141,335
-21% -$33.5M 0.08% 213
2021
Q4
$145M Buy
659,371
+79,762
+14% +$15.5M 0.08% 229
2021
Q3
$105M Sell
579,609
-120,472
-17% -$23.5M 0.06% 278
2021
Q2
$141M Buy
700,081
+61,546
+10% +$12.9M 0.09% 210
2021
Q1
$137M Buy
638,535
+132,354
+26% +$29.1M 0.09% 214
2020
Q4
$120M Buy
506,181
+172,180
+52% +$39.5M 0.07% 250
2020
Q3
$90.9M Sell
334,001
-30,379
-8% -$8.38M 0.06% 264
2020
Q2
$106M Buy
364,380
+124,655
+52% +$33.8M 0.08% 204
2020
Q1
$57M Buy
239,725
+6,115
+3% +$1.4M 0.05% 319
2019
Q4
$51.1M Sell
233,610
-86,088
-27% -$17.4M 0.04% 497
2019
Q3
$54.2M Sell
319,698
-54,623
-15% -$9.66M 0.04% 413
2019
Q2
$68.6M Buy
374,321
+119,212
+47% +$20.8M 0.06% 329
2019
Q1
$46.9M Buy
255,109
+39,637
+18% +$7.32M 0.05% 416
2018
Q4
$35.7M Buy
215,472
+41,995
+24% +$7.28M 0.04% 530
2018
Q3
$33.4M Buy
173,477
+73,630
+74% +$13.1M 0.03% 556
2018
Q2
$17M Sell
99,847
-85,780
-46% -$13.3M 0.02% 908
2018
Q1
$30.3M Buy
185,627
+27,114
+17% +$4.43M 0.02% 579
2017
Q4
$23.8M Buy
158,513
+20,162
+15% +$2.99M 0.02% 751
2017
Q3
$21M Sell
138,351
-46,855
-25% -$7.05M 0.02% 767
2017
Q2
$23.9M Buy
185,206
+4,563
+3% +$549K 0.02% 673
2017
Q1
$19.8M Sell
180,643
-34,053
-16% -$3M 0.02% 745
2016
Q4
$15.8M Buy
214,696
+146,012
+213% +$11.9M 0.01% 903
2016
Q3
$5.99M Sell
68,684
-10,129
-13% -$957K 0.01% 1507
2016
Q2
$6.78M Sell
78,813
-24,301
-24% -$2.1M 0.01% 1303
2016
Q1
$8.2M Buy
103,114
+29,352
+40% +$2.65M 0.01% 1149
2015
Q4
$9.28M Sell
73,762
-58,233
-44% -$7.03M 0.01% 1203
2015
Q3
$13.7M Sell
131,995
-7,988
-6% -$1.03M 0.01% 923
2015
Q2
$17.3M Sell
139,983
-39,044
-22% -$4.92M 0.02% 866
2015
Q1
$21.1M Sell
179,027
-2,627
-1% -$315K 0.02% 740
2014
Q4
$21.6M Buy
181,654
+19,091
+12% +$2.15M 0.02% 766
2014
Q3
$18.3M Sell
162,563
-220,559
-58% -$21M 0.02% 860
2014
Q2
$36.3M Buy
383,122
+200,774
+110% +$14.1M 0.03% 482
2014
Q1
$12.9M Sell
182,348
-15,974
-8% -$1.27M 0.01% 984
2013
Q4
$14.7M Buy
198,322
+19,625
+11% +$1.37M 0.01% 952
2013
Q3
$13.5M Buy
178,697
+63,709
+55% +$5.07M 0.01% 947
2013
Q2
$9.18M Buy
+114,988
New +$8.47M 0.01% 1142

Other funds holding VRTX

Citigroup's VRTX Position: Q1 2026 in Review

Citigroup increased its Vertex Pharmaceuticals (VRTX) stake by 26% in Q1 2026, buying an estimated $66.6M and bringing the position to 682,807 shares worth $305M. The position accounts for 0.13% of the portfolio, ranked #153.

Citigroup first reported a position in VRTX in Q2 2013 and has held it in 52 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Citigroup held 682,807 shares of Vertex Pharmaceuticals worth $305M as of Q1 2026.
  • Citigroup bought 142,877 Vertex Pharmaceuticals shares in Q1 2026, an estimated $66.6M.
  • Vertex Pharmaceuticals made up 0.13% of Citigroup's portfolio in Q1 2026, its #153 holding.
  • Citigroup first reported a position in Vertex Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.